- Conditions
- Healthy Participants
- Interventions
- Afimetoran, Phenytoin, Midazolam
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 6,229
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Aging
- Interventions
- Dance Group, Strength, Stretching, Stability, Walking, Walking + Nutrition
- Behavioral
- Lead sponsor
- University of Illinois at Urbana-Champaign
- Other
- Eligibility
- 60 Years to 79 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Urbana, Illinois
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Partial Oncolysis, SV-102
- Procedure · Drug
- Lead sponsor
- Syncromune, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 19 more
- Conditions
- HIV-1-infection
- Interventions
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 44 more
- Conditions
- Dyslipidaemias, Dyslipidemias
- Interventions
- 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 21
- States / cities
- Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more
- Conditions
- Healthy Volunteers
- Interventions
- Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
- Interventions
- FAM ACT, I-DSMES
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Pittsburgh, Pennsylvania
- Conditions
- Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
- Interventions
- CAN04, Pembrolizumab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Cantargia AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Lake Mary, Florida • Philadelphia, Pennsylvania
- Conditions
- Cervical Dystonia Adults ,, Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
- Interventions
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
- Drug
- Lead sponsor
- li nguyen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Westminster, California
- Conditions
- FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Other Solid Tumors, Adult
- Interventions
- RLY-4008
- Drug
- Lead sponsor
- Elevar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
- Conditions
- Dry Eye, Eye Strain, Visual Acuity, Color Perception
- Interventions
- Gunnar OTC Glasses
- Device
- Lead sponsor
- Pacific University
- Other
- Eligibility
- 18 Years to 42 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Forest Grove, Oregon
- Conditions
- Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
- Interventions
- Elimusertib (BAY1895344), Niraparib
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Relapsed/ Refractory Multiple Myeloma
- Interventions
- Talquetamab, Teclistamab, PD-1 Inhibitor
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Denver, Colorado • New York, New York • Winston-Salem, North Carolina + 1 more
- Conditions
- Healthy Study Participants
- Interventions
- glovadalen, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Alcohol Drinking, Binge Drinking, Text Messaging
- Interventions
- Brief Alcohol Intervention, Automated and Targeted Text Messages
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Autism Spectrum Disorder
- Interventions
- Autism Pupil Screen (APS) Detect PLR Assessment #1, Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT/R-F), Social Responsiveness Scale, Second Edition (SRS-2), Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Mullen Scales of Early Learning (MSEL), Adaptive Behavior Assessment System, Third Edition (ABAS-3), Autism Pupil Screen (APS) Detect PLR Assessment #2, Autism Pupil Screen (APS) Detect Assessment #3, Well-child check
- Device · Other · Diagnostic Test + 1 more
- Lead sponsor
- Schweitzer Engineering Laboratories
- Industry
- Eligibility
- 24 Months to 60 Months
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Lewiston, Idaho • Moscow, Idaho • Pullman, Washington
- Conditions
- Head And Neck Cancer
- Interventions
- Swallowing Exercises, Symptom Inventory, Questionnaires
- Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 585 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 52
- States / cities
- Cullman, Alabama • Homewood, Alabama • Irvine, California + 45 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-06291874, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Anaheim, California • Chula Vista, California • South Miami, Florida
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- azacitidine, lenalidomide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Solid Tumor
- Interventions
- MTB-9655
- Drug
- Lead sponsor
- MetaboMed Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hypertension, Health Behavior, Healthcare Patient Acceptance, Patient Engagement, Adherence, Patient
- Interventions
- Remote Patient Monitoring, Self-monitoring of hypertension-related factors, Immediate financial incentives, Delayed financial incentives
- Behavioral
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Bastrop, Louisiana • Shreveport, Louisiana
- Conditions
- Neoplasms
- Interventions
- JNJ-88549968, Ruxolitinib, Momelotinib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Goodyear, Arizona • Duarte, California • Aurora, Colorado + 15 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Ocrevus
- Drug
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey